Navigation Links
Discovery may help prevent HIV 'reservoirs' from forming

April 17, 2013 (BRONX, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the protein that blocks HIV-1 from multiplying in white blood cells is regulated. HIV-1 is the virus that causes AIDS, and the discovery could lead to novel approaches for addressing HIV-1 "in hiding" namely eliminating reservoirs of HIV-1 that persist in patients undergoing antiretroviral therapy. The study was published today in the online edition of the journal Cell Host & Microbe.

Antiretroviral therapy can reduce blood levels of HIV-1 until they are undetectable. But despite drug therapy, reservoirs of HIV-1 can persist in several types of white cells, notably macrophages important immune cells that help clear pathogens and other potentially harmful substances from the body.

"If you stop antiretroviral therapy, the virus emerges from these reservoirs and returns to the general circulation in a matter of days, as if the patient had never been treated," said senior author Felipe Diaz-Griffero, Ph.D., assistant professor of microbiology & immunology at Einstein. "Now we know the protein that we need to control so we can prevent HIV-1 reservoirs from forming or eliminate them entirely."

Scientists have known that a protein called SAMHD1 prevents HIV-1 from replicating in certain immune cells. But until now, it was not understood why SAMHD1 fails to function in immune cells like macrophages that are vulnerable to HIV-1 infection.

Using mass spectrometry, a tool for determining molecular composition, Dr. Diaz-Griffero found that SAMHD1 can exist in two configurations known as phosphorylated and unphosphorylated. (Phosphorylation is an important cellular process in which phosphate groups attach to other molecules, thereby activating various signaling and regulatory mechanisms within the cell.) When SAMHD1 is phosphorylated the situation in immune cells that divide the cell is not protected from being infected with HIV-1. When the protein is not phosphorylated as occurs in the nondividing macrophages the cell is protected from HIV infection.

"We are currently exploring ways to keep this protein unphosphorylated so that HIV reservoirs will never be formed," said Dr. Diaz-Griffero.


Contact: Deirdre Branley
Albert Einstein College of Medicine

Related biology news :

1. An important discovery in breast cancer by IRCM researchers
2. Genetic discovery found to influence obesity in people of African ancestry
3. Accidental discovery may lead to improved polymers
4. Gene discovery may yield lettuce that will sprout in hot weather
5. UGA discovery may allow scientists to make fuel from CO2 in the atmosphere
6. Discovery could increase efficacy of promising cystic fibrosis drug
7. Discovery of first motor with revolution motion in a virus-killing bacteria advances nanotechnology
8. Discovery could yield treatment for cocaine addicts
9. Discovery may explain how prion diseases spread between different types of animals
10. Gene discovery reveals importance of eating your greens
11. IU discovery on animal memory opens doors to research on memory impairment diseases
Post Your Comments:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
Breaking Biology Technology: